Video

CML: Improving Treatment for Patients Who Don't Respond

Transcript:

Related Videos
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Hua-Jay “Jeff” Cherng, MD, assistant professor, medicine, Lymphoma Program, Division of Hematology and Oncology, Columbia University Irving Medical Center
Naval G. Daver, MD
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)
Joseph Maakaron, MD, assistant professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Marie Hu, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, the University of Minnesota Medical School
Harry P. Erba, MD, PhD